1
+
Use Cases
Download Pitch Deck
more+
Creativity, Unleashed.
AiCenna Healthcare
Redefining Precision Health Through AI, IoT & Genomics
AiCenna is a US-based healthcare technology company building the future of preventive medicine through
Digital Twin technology—integrating real-time biosensing, genomics, and AI-driven simulations.
About us
Who We Are
AiCenna, a subsidiary of Elixem Holdings LLC, is headquartered in the US with strategic leadership and clinical infrastructure in Dubai and Pakistan.
Our goal is to transform reactive healthcare into a personalized, proactive, and predictive system.
AiCenna, a subsidiary of Elixem Holdings LLC, is headquartered in the US with strategic leadership and clinical infrastructure in Dubai and Pakistan.
Our goal is to transform reactive healthcare into a personalized, proactive, and predictive system.
Our Vision
To revolutionize preventive healthcare by integrating AI, IoT, and genomics for real-time, personalized disease management.
The Problem We Address
Development & Roadmap
Platform Components:
Our Approach is Built Around A Three-Phase Process.
01
Feb–Mar Concept & Prototypes
We'll lean on our deep expertise with AI to identify areas where we can implement tools and systems to drive tangible results.
02
Apr–Jul Infrastructure & Pre-Releases
Based on the findings of the audit, we craft a bespoke suite of AI-driven technology aligns with your strategic goals.
03
Aug–Dec Full UAT, Integration & Final Version
Once the technology has been configured, we begin implementing.
Roadmap & Milestones
Interactive Gantt-style timeline with key product phases:
Demo & Walkthroughs
App Demo with 200+ usecases
Meet Our Professional Team Member
Dr. Salman Gillani
Founder
Dr. Mobeen
Director
Billal Shah
Creative Director
K. Shoaib Ahmad
Chief Technology Officer
Investment & Ask
We are raising $3 million in pre-launch equity funding, offering a 15% stake at a $20M post-money valuation. This capital provides an estimated 18-month runway, covering operational costs of ~$167K/month through end of 2026.
The platform launches in Q3 2025, with revenue generation starting January 2026. We project to reach $1.5 million in Year 1 (2026), and scale to $5.7 million by 2028, driven by SaaS subscriptions, clinical partnerships, and B2B licensing.
With a gross margin stabilizing around 66%, the business model becomes cash-flow efficient early, enabling compounding growth.
Why Invest?
First-of-its-kind
one-window platform combining biosensing, genomics, AI, and clinical insight
Customizable, scalable, and regulation-ready
Built-in MedAI Studio empowers real-time model evolution by clinicians
Clear path to revenue via tiered pricing and enterprise integration
Positioned to lead the next wave in AI-powered preventive care
Tiered Early Investor Incentives
“ Early Ally Bonus ”
“ Early Ally Bonus ”
$
1,000
Investment
- 3 Months Free Subscription on Hybrid Tier or lower
- “Founding Ally – 2025” Badge
- Priority Beta Access to core app features and health innovations
- Referral Boost: 10% Bonus Credit per successful referral
- Quarterly Product Insider Newsletter
"AI Pioneer Advantage"
"AI Pioneer Advantage"
$
5000
Investment
- 6 months free on any Hybrid Tier or lower-level subscription
- Investor Recognition Badge inside the app/profile (e.g., “Founding Member – 2025”)
- Priority access to beta features, app upgrades, and early access to health innovations
- Invitation to Annual HealthTech Roundtable (virtual event with founders, doctors, and technologists)
- Referral Boost: 20% bonus credit for every referred subscriber (up to $1,000 in credit)
"Digital Health Visionary"
"Digital Health Visionary"
$
10000
Investment
- 12 months free on Premium Tier (Concierge Services included)
- Lifetime discounted renewal rate (e.g., 20% off all tiers for life)
- Co-branding Opportunity: “Visionary Backer” tag visible in patient dashboard (opt-in)
- 1:1 Quarterly Health Strategy Call with top health advisor (first 2 years)
- VIP Launch Event Invite – physical or hybrid presence at major product milestone launch
- Exclusive access to performance reports, company updates, and investor pre-briefings
FAQ
Frequently Asked Question
Legal
• Ownership: Subsidiary of Elixem Holdings LLC (Dubai)
• Incorporation: U.S.-based operating company with UAE backing
• Regulatory: Aligning with FDA, UAE, and Pakistan health authorities
• Incorporation: U.S.-based operating company with UAE backing
• Regulatory: Aligning with FDA, UAE, and Pakistan health authorities
Financial
• Equity Structure: Common shares
• Valuation: ~$10M post-money
• Funding to Date: No external debt; internally financed
• Launch Target: June 30, 2025
• Valuation: ~$10M post-money
• Funding to Date: No external debt; internally financed
• Launch Target: June 30, 2025
Technical
• Built-in integration with Elixem’s regenerative medicine clinics
• Real-time health data simulation
• Phase 1: 2 hospitals, 10,000 users, 3 insurance pilots
• Real-time health data simulation
• Phase 1: 2 hospitals, 10,000 users, 3 insurance pilots
Your next big investment portfolio’s just one click away.
MedAI Studio
Activity Tracker
Health Profile
Nutrition Tracking
IoT Support
Advance Ai Tech
# 1 Healthcare App
